Equities

Mayne Pharma Group Ltd

Mayne Pharma Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)7.24
  • Today's Change0.02 / 0.28%
  • Shares traded147.58k
  • 1 Year change+92.55%
  • Beta1.1435
Data delayed at least 20 minutes, as of Mar 28 2024 05:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.

  • Revenue in AUD (TTM)278.45m
  • Net income in AUD-258.82m
  • Incorporated2005
  • Employees900.00
  • Location
    Mayne Pharma Group Ltd1538 Main North RdADELAIDE 5106AustraliaAUS
  • Phone+61 88209-2666
  • Fax+61 88281-0284
  • Websitehttp://www.maynepharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Botanix Pharmaceuticals Ltd200.38k-10.02m346.53m1.00--7.50--1,729.37-0.0072-0.00720.00020.02930.0059--1.09---29.28-67.71-32.25-81.15-----5,002.57-8,798.518.14-138.170.00--351.94-6.2530.50------
PYC Therapeutics Ltd21.54m-21.65m428.79m23.00--10.36--19.90-0.006-0.0060.00620.0080.6034--2.48---60.70-41.67-81.23-46.95-----100.60-178.69---50.320.0174---1.11218.52-64.39--18.46--
Immutep Ltd256.62k-40.50m439.87m19.00--3.80--1,714.09-0.0394-0.03940.00030.09730.0025--2.48---38.61-36.31-41.57-39.21-----15,782.59-919.13----0.0138---24.64-51.34-23.86--47.40--
Opthea Ltd179.27k-247.41m490.48m5.00------2,735.97-0.4742-0.47420.0004-0.10840.0007--0.1772---100.84-90.04-116.05-100.93-99.74-197.19-138,008.10-69,641.71---29.641.35--19.55-34.31-53.55---3.82--
Mesoblast Ltd11.43m-111.85m564.65m83.00--0.645--49.40-0.1356-0.13560.0140.76750.0112--3.71137,709.00-10.92-12.66-11.67-13.92-190.91-78.09-978.54-593.91---3.010.1934---26.56-15.4310.35--5.60--
Mayne Pharma Group Ltd278.45m-258.82m614.24m900.00--1.07--2.21-3.18-2.993.436.740.21050.81921.37---19.56-14.47-26.66-18.0568.0550.60-92.95-64.691.30-5.680.0626--20.75-18.54-51.49--18.41--
Clinuvel Pharmaceuticals Limited87.46m30.15m710.80m16.0024.343.9822.828.130.58250.58251.693.560.4702-0.95147.37--16.2121.2518.5723.55109.26--34.4841.846.4312.110.0067.4424.2726.1446.5818.2768.7420.11
Clarity Pharmaceuticals Ltd11.80m-30.56m749.91m----14.09--63.55-0.117-0.1170.04520.20230.1596--0.8407---41.34---45.22-------258.98------0.00--77.98---3.57------
Imugene Ltd0.00-89.24m768.43m0.00--3.86-----0.0132-0.01320.000.02720.00-------40.29-26.64-43.53-28.00------------0.021-------0.1207------
Data as of Mar 28 2024. Currency figures normalised to Mayne Pharma Group Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

24.13%Per cent of shares held by top holders
HolderShares% Held
Investors Mutual Ltd.as of 10 Aug 20224.40m5.18%
Rubric Capital Management LPas of 18 Sep 20234.36m5.12%
Lazard Asset Management Pacific Co.as of 13 Jun 20234.24m4.99%
The Vanguard Group, Inc.as of 07 Mar 20242.81m3.31%
Dimensional Fund Advisors LPas of 07 Mar 20241.22m1.43%
Vanguard Investments Australia Ltd.as of 29 Feb 20241.18m1.39%
UBS AG (Investment Management)as of 14 Mar 2024640.13k0.75%
DFA Australia Ltd.as of 29 Feb 2024637.17k0.75%
Norges Bank Investment Managementas of 31 Dec 2023555.30k0.65%
UBS Asset Management (Australia) Ltd.as of 14 Mar 2024478.45k0.56%
More ▼
Data from 30 Nov 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.